Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Authors: Alsoussi et al. 

Journal/ Pre-Print:Journal of Immunology  

Key Words: Immunology, Antibody 

Research Highlights

  1. Generation and characterization of a panel of murine monoclonal antibodies (mAbs) directed against the receptor-binding domain (RBD) 

  1. Antibody 2B04 is shown to both neutralize SARS-CoV-2 very potently in vitro and in vivo in a mouse model. 


This study aims to identify potent neutralising mAb against SARS-CoV2 RBD for the purpose of generating antibodies for therapy.  Mice were immunized with recombinant SARS-CoV-2 RBD and adjuvant and boosted 14 days later twice with recombinant SARS-CoV-2 spike (S) protein at a 10-day interval. 5 days after the final booster immunization potent neutralizing serum activity was measured against recombinant S or RBD protein and anti-SARS-CoV-2 antibodies were isolated and cloned from sorted plasma blasts. Five isolated antibodies were shown to display strong neutralizing activity against SARS-CoV-2 in vitro, amongst which the antibody clone 2B04 showed the most potent activity. In vivo protective activity of 2B04 was tested using a mouse model of SARS-CoV-2 infection in which hACE2 is transiently expressed via a nonreplicating adenoviral vector. 2B04 was shown to limit disease and reduce viral dissemination. 

Impact for SARS-CoV2/COVID19 research efforts  

Inhibit of SARS-CoV2/COVID19 transmission 

Treat of SARS-CoV2/COVID19 positive individuals 

Study Type 

  • In vitro study 

  • In vivo study (e.g. mouse, NHP) 

Strengths and limitations of the paper 

Novelty: Potently neutralizing anti-SARS-CoV-2 antibodies have been isolated previously 

Standing in the field:There is already a couple of papers published reporting similar results with other mAb. 

Appropriate statistics: Yes 

Viral model used:They use wild-type SARS-CoV-2 for their in vitro assay and the strain 2019 n-CoV/USA_WA1/2020 for their in vivo infection  

Translatability:2B04 could be developed as a therapy 

Main limitations: They generate mouse antibodies and show in vivo efficacy only in mice